12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Merus Labs International, Novartis sales and marketing update

Merus acquired from Novartis rights to manufacture and market overactive bladder (OAB) drug Emselex darifenacin in Canada and the EU, excluding France, Spain and Italy. Merus funded the acquisition...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >